Abstract: A detachable supporting device includes a base, an external component and a supporting portion. The base is put on a holding surface. The external component is detachably disposed on the base. A bar of the external component has a first end and a second end. A first magnetic member is disposed on the first end. A second magnetic member is disposed between the first end and the second end. The supporting portion is connected to the base. The supporting portion includes a first magnetic unit and at least one second magnetic unit. The first magnetic unit and the at least one second magnetic unit are disposed on different sides of the base respectively, wherein the first magnetic unit cooperates with the first magnetic member to provide a magnetic attraction force and the second magnetic unit cooperates with the second magnetic member to provide a magnetic repulsion force.

Abstract: A detachable supporting device includes a base and a magnetic force providing module. The base has a body portion and a stretching portion. The magnetic force providing module has a first magnetic component, a first magnetic assembly and a second magnetic assembly. The first magnetic component is disposed on the stretching portion. The first magnetic assembly includes a second magnetic component and a third magnetic component. Two poles of the second magnetic component respectively face an upper surface and a lower surface of the body portion. A pole of the third magnetic component faces the second magnetic component. The second magnetic assembly includes a fourth magnetic component and a fifth magnetic component. Two poles of the fourth magnetic component respectively face the upper surface and the lower surface. A pole of the fifth magnetic component faces the fourth magnetic component.

Abstract: A detachable supporting device includes a base, an external component and a supporting portion. The base is put on a holding surface. The external component is detachably disposed on the base. A bar of the external component has a first end and a second end. A first magnetic member is disposed on the first end. A second magnetic member is disposed between the first end and the second end. The supporting portion is connected to the base. The supporting portion includes a first magnetic unit and at least one second magnetic unit. The first magnetic unit and the at least one second magnetic unit are disposed on different sides of the base respectively, wherein the first magnetic unit cooperates with the first magnetic member to provide a magnetic attraction force and the second magnetic unit cooperates with the second magnetic member to provide a magnetic repulsion force.

Abstract: Methods and compositions for treating retinal diseases comprising therapeutic amounts of a compound selected from a normal Puf-A gene product, an active polypeptide fragment thereof, an analog thereof or a peptidomimetic thereof. Vectors, including AAV vectors comprising the therapeutic compound are provided. Puf-A compositions suitable for subretinal, intravitreal, topical, subconjunctival, retrobulbar, periocular, suprachoroidal, or intraocular administration are provided. Methods for screening siRNA, RNAi and shRNA, small molecules and monoclonal antibodies that inhibit Puf-A target activity and reduce apoptosis are provided.

Abstract: An adjustable connecting seat is connected with a point-of-service display. The adjustable connecting seat includes a base, a rotating mechanism, and a supporting mechanism. The rotating mechanism includes a first disk and a second disk. The first disk and the second disk are rotatable relative to each other. The second disk is fixed on the base. The supporting mechanism is connected with the rotating mechanism and the point-of-service display. Consequently, the point-of-service display is rotatable by the rotating mechanism.

Abstract: Methods and compositions for treating retinal diseases comprising therapeutic amounts of a compound selected from a normal Puf-A gene product, an active polypeptide fragment thereof, an analog thereof or a peptidomimetic thereof. Vectors, including AAV vectors comprising the therapeutic compound are provided. Puf-A compositions suitable for subretinal, intravitreal, topical, subconjunctival, retrobulbar, periocular, suprachoroidal, or intraocular administration are provided. Methods for screening siRNA, RNAi and shRNA, small molecules and monoclonal antibodies that inhibit Puf-A target activity and reduce apoptosis are provided.

Abstract: A touch panel module includes a frame unit and a touch panel unit. The frame unit includes a hollow frame body. The hollow frame body has a receiving space concaved downwardly from the top side thereof, a surrounding positioning portion formed on an inner bottom surface thereof, and an inner ladder structure formed on an inner surrounding peripheral surface thereof. The touch panel unit includes a transparent substrate received in the receiving space and disposed on the surrounding positioning portion by a plurality of adhesive elements and a transparent conductive film received in the receiving space and disposed on the transparent substrate. Therefore, the touch panel unit can naturally aim at the center position inside the hollow frame body due to the design of the inner ladder structure of the hollow frame body.